High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
Authors (first, second and last of 20)

Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.
The Editor-in-Chief is Arnold Ganser, Department of Hematology, Hemostasis and Oncology, Medizinische Hochschule Hannover.
Why publish with us
The Editor-in-Chief of Annals of Hematology acknowledges the quality of papers by choosing in each issue one article that is outstanding with respect to scientific quality and public-health relevance.
We invite you to read the most recently published articles in Annals of Hematology on emerging COVID-19 research.
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.